Introduction
The importance of membrane phospholipids in the regulation of key cellular functions has been widely demonstrated in the last decades. Among these, cell proliferation, transformation and apoptosis, have been extensively studied (Majerus et al., 1986; Berridge, 1993; Lacal and Carnero, 1994; Lacal, 1997) . One of the key enzymes in these processes is Phospholipase D (PLD), that catalyses the hydrolysis of phosphatidylcholine (PC) to generate both choline (Cho) and phosphatidic acid (PA). PA can be further deacylated to LPA by phospholipase A2. Alternatively, PA can suer dephosphorylation by a phosphatidic acid hydrolase (PAH) to generate DAG. Both LPA and DAG are known to be mitogens (Billah and Anthes, 1990; van Corven et al., 1989; Jalink et al., 1990) . Phosphorylation of choline by ChoK causes an elevation of phosphorylcholine (PCho) levels, implicated in proliferation and cellular transformation (Cuadrado et al., 1993; JimeÂ nez et al., 1995; Singer et al., 1995; Bhakoo et al., 1996; HernaÂ ndezAlcoceba et al., 1997) .
Given that PC is the most abundant membrane phospholipid in eukaryotic cells, its hydrolysis can sustain the long-lasting release of mitogenic second messengers that can be necessary in proliferation and transformation (Lacal and Garnero, 1994; Lacal, 1997) . Therefore, it is not surprising that certain oncogenes such as ras, rho and src induce the activation of PLD (Carnero et al., 1994a,b; Song et al., 1991; Malcolm et al., 1996; Lacal, 1990; Carnero and Lacal, 1995) . Growth factors and oncogenes activate PLD following alternative but cross talking pathways in murine ®broblasts (del Peso et al., 1996 (del Peso et al., , 1997 . In addition, PLD activation has been implicated in the acquisition of invasive capacity of cells, one of the most important components of the metastatic phenotype (Imamura et al., 1993; HernaÂ ndez-Alcoceba et al., 2000) . This raises the possibility of considering phospholipid metabolism as a potential target for the development of new antitumoral agents in an attempt to diversify the mechanism of action of antitumor drugs (Powis et al., 1995; Wieder et al., 1999) .
In the last two decades, new families of membraneactive agents based on the structure of phospholipids have emerged, which have shown promising anticancer activity. Among them, HePC, an alkylphosphocholine, is one of the best-characterized members of this kind of compounds. The eect of ether-linked phospholipid analogues on PLD is somewhat controversial. It has been recently reported that HePC induces a rapid activation of PLD activity, which is completely blocked by PKC inhibition (Wieder et al., 1996) . The existence of a PKC-dependent PLD stimulation by HePC seems contradictory with previous results showing inhibition of PKC by this substance (U È berall et al., 1991; Zeng et al., 1990) .
In a attempt to clarify this issue, we have analysed the eect of HePC on the basal and phorbol-ester stimulated PLD activity and on ChoK, two enzymes involved in PC metabolism recently reported to play a role in cellular transformation (HernaÂ ndez-Alcoceba et al., 1997; Lu et al., 2000) . The results obtained indicate the existence of PKC-dependent or independent mechanisms for PLD activation, depending on cell type, and a general loss of response of PLD activation after chronic treatment with HePC. By contrast no eect on ChoK was observed. A new model for HePC mechanism of action is proposed.
Results

HePC activates PLD
We investigated the putative involvement of PLD in the antiproliferative activity of the lipid-derived drug HePC. First, we studied the eects on PLD activity after treatment with the drug by the rather speci®c transphosphatidylating activity assay. As shown in Figure 1a , acute treatment of MDCK cells with HePC induced a dose-dependent activation of PLD. Similar results were also observed when NIH3T3 or Rat-2 cells were used (Figure 1b and c) . Thus, HePC caused a strong dose-dependent stimulation of PLD activity in all three NIH3T3, Rat-2 and MDCK cells which was at least comparable to a saturating concentration of phorbol esters. Activation of PKC by phorbol esters is a potent system for the activation of PLD. The relevance of this pathway is supported by the fact that growth factors use a PKC-dependent mechanism for PLD activation (del Peso et al., 1997) . Thus, we investigated whether activation of PLD by HePC depends upon PKC. To that end, we ®rst inhibited PKC by treatment of MDCK and Rat-2 cells with PDBu at 1 mM for 4 h, or 350 nM during the labeling period for NIH3T3 cells. This treatment was sucient to induce full downregulation of PKC. As shown in Figure 2 this procedure completely abrogated the subsequent stimulation of PLD by PDBu, but HePC retained its stimulating activity (Figure 2a) . Similar results were obtained after treatment with 500 nM PDBu for 12 h (data not shown) or when PKC was inhibited with the speci®c inhibitors GoÈ 6976 (Figure 2b) , GoÈ 6983 or Bisindolylmaleimide (data not shown). In contrast with these results, no stimulation of PLD was achieved in Rat-2 and NIH3T3 cells with HePC treatment after the downregulation of PKC by phorbol esters, indicating that a PKC-dependent mechanism is involved in PLD activation by HePC in Rat-2 and NIH3T3 cells ( Figure  2c,d) .
Phorbol esters treatment are known to downregulate all DAG-sensitive PKC species, while GoÈ 6976 is a selective inhibitor for the Ca 2+ -and DAG-dependent PKCa, bI and bII isozymes, and GoÈ 6983 and Bisindolylmaleimide inhibit also PKCg, PKCd, PKCm, PKCe and PKCz (Ku et al., 1997; Gschwendt, 1996; Pazit and Liscovitch, 1989) . These results suggest that HePC can activate PLD in MDCK cells following a mechanism independent of PKC ( Figure 2b ). 
Chronic treatment with HePC induces loss of PLD activation
Since direct activation of PKC stimulates PLD in all cells tested, we next investigated whether HePC treatment aected the PKC-dependent activation of PLD. Consequently, the eect of chronic treatment with HePC on PLD activity by phorbol esters was investigated. Cells were incubated in the presence of HePC for dierent periods (as described in ®gure legends for each cell line) and then treated with either 350 nM PDBu or 50 mM HePC for the activation of PLD. As shown in Figure 3 , a prolonged exposure to HePC induced a drastic reduction of 70 ± 75% in the subsequent stimulation of PLD by either phorbol esters or HePC in all mammalian cell lines tested. However, after treatment of the MDCK cells with 12.5 mM HePC for 12 h, or the treatment of NIH3T3 cells with 50 mM for 6 days, PLD activation by either PDBu or HePC was normal (data not shown). Unspeci®c eects due to toxicity were ruled out as determined by the exclusion of Trypan blue stain after 24 h of HePC treatment in MDCK cells (data not shown). These results indicate that chronic treatment with HePC induces an inhibitory eect on PLD activity. This inhibition suggests that HePC could act on PLD either directly or through PKC, but in both cases prevented the subsequent stimulation of the enzyme by PKC or HePC.
HePC activates both PLD1 and PLD2
In order to study which isoform of PLD (PLD1 and PLD2) was implicated in the activation (acute treatment) or inhibition (chronic treatment) by HePC, we transfected transiently both isoforms in HEK 293T cells and measured PLD activity after HePC treatment. As shown in Figure 4a , HePC eciently activated both PLD1 and PLD2 isoforms. Furthermore, chronic treatment with HePC had an eect on both isoforms as shown by a reduction of 30 ± 50% on its activation by a saturating concentration of HePC.
The above eect on PLD activation could be explained if a chronic stimulation of PLD by HePC induced its downregulation by speci®c proteolysis, similar to what has been described for PKC activation and downregulation by phorbol esters (Plevin et al., 1991) . Thus, we tested by Western blot the total amount of PLD1 and PLD2 in transfected cells chronically treated with HePC. No detectable alteration in the total levels of PLD using an anti-HA antibody was observed after 24 h of treatment with 15 mM HePC (Figure 4b) , while a reduction of 30 ± 50% in the stimulation of PLD by HePC could be observed (Figure 4a) . Thus, the inhibitory eect of PLD isoforms activation observed by chronic treatment with HePC is not due to a selective degradation of the enzymes.
HePC does not affect ChoK
HePC contains a phosphorylcholine moiety in its structure, and therefore could also potentially interfere with ChoK activity, being this the basis for their antitumor activity. Thus, we investigated whether the antiproliferative eect of this drug was related to their interference with ChoK function.
First, the ability of these compounds to directly aect the enzymatic activity of ChoK by a standard ex vivo assay was performed as previously described , 1997, 1999) . Puri®ed ChoK was assayed in the presence of dierent concentrations of the highly speci®c inhibitor JCR-947A (HernaÂ ndez-Alcoceba et al., 1997), or HePC to a concentration of up to 150 mM. As shown in Figure 5a , no inhibitory eect on ChoK was observed by HePC under conditions where a drastic reduction by the speci®c ChoK inhibitor JCR-947A was achieved. Thus, HePC was not able to interfere directly with the enzymatic activity of ChoK.
Finally, the eect of HePC on ChoK in mammalian cells was also investigated. Cell extracts from MDCK and HT29 cells were incubated in the presence of 40 mM JCR-947A or 50 mM HePC along with 0.5 mCi/ ml methyl-[ 14 C]choline chloride for 30 min at 378C. After the incubation period, ChoK activity was estimated by the conversion rate of radioactive choline into PCho as described under Materials and methods. As shown in Figure 5b , HePC observed no signi®cant eect on the ChoK activity either under these conditions. Thus, the antiproliferative eect of these drugs is not related to interference with the ChoK function.
Discussion
Several lines of evidence support the implication of PLD in signal transduction pathways controlling mitogenesis. The regulation of this phospholipase follows a complex mechanism, which is only recently Figure 4 Chronic treatment with HePC aect PLD1 and PLD2 activity. HEK 293T cells were transiently transfected with none, PLD1 and PLD2 isoforms and PLD activity measured after HePC treatment. (a) Cells were isotopically radiolabeled with 14 Cglycerol for 24 h and were untreated or treated with 15 mM HePC during the labeling period. Washed cells were incubated in a serum free medium with none, or 50 mM HePC for 30 min in the presence of 1-butanol. PLD activity was measured by transphosphatidylation. (b) Western blot using an anti-HA antibody. Cells were grown to con¯uence in DMEM supplemented with 10% fetal calf serum and treated with none or 15 mM HePC for 24 h. After incubation cells were lysed and equivalent amounts of cells extracts (20 mg) resolved by SDS ± PAGE, transferred to nitrocellulose paper and blotted as described in Materials and methods
Figure 5
Eect of HePC on ChoK activity. (a) Dierent concentrations of either HePC or JCR-947A were incubated for 30 min at 378C with 10 mU/ml ChoK from yeast in a buer containing 100 mM Tris pH 8, 100 mM MgCl 2 , 10 mM ATP and 200 mM methyl-( 14 C)-choline chloride (55 mCi/mmol, 2 mCi/ml) stopped reaction on ice by adding 10 ml 500 mM EDTA. (b) Cells were lysed with a lysis buer (150 mM NaCl, 0.5% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 7.5, 15 mM bglycerophosphate, 10 mM Na 4 P 2 O 7 , 50 mM NaF, 0.1 mM Na 3 VO 4 , 20 mg/ml leupeptin, 1 mM PMSF). After 20 min centrifugation, 100 mg of protein were assayed for ChoK activity in the presence of 50 mM of HePC or 40 mM JCR-947A. Samples were resolved in thin layer chromatography plates (LK6D Silica gel 60A, Whatman Inc. New Jersey, USA). Radioactive metabolites (Choline and Phosphocholine) were automatically quanti®ed by an electronic autoradiography system (Instantimager, Packard; Meriden, CT, USA) being clari®ed. Phorbol esters and growth factors like platelet-derived growth factor (PDGF) activate PLD by a PKC-dependent pathway (Lacal and Carnero, 1994; Lacal, 1997; del Peso et al., 1996 del Peso et al., , 1997 . On the other hand, oncogenes such as ras activate PLD by a mechanism independent of PKC that may involve the GTPase Ral, a member of the Ras superfamily (Lacal and Carnero, 1994; Lacal, 1997; Carnero et al., 1994a, b; Carnero and Lacal, 1995; del Peso et al., 1996 del Peso et al., , 1997 Jiang et al., 1995) . Finally, other small GTPases of the Ras superfamily, such as ARF and members of the Rho family can directly interact and activate PLD (Han et al., 1998; Exton, 2000) . Although there is abundant information demonstrating activation of PLD by mitogenic stimulation of cells by growth factors, its involvement in the regulation of cell growth is not fully understood. Recently it has been demonstrated that Ras proteins are involved in the physiological regulation of PLD by PDGF (Lucas et al., 2000) . On the other hand, PLD has been implicated in the acquisition of the transforming potential of murine ®broblasts (Lu et al., 2000) or the invasive capacity of transformed cells (Imamura et al., 1993) one of the most important determinants of malignant behavior (HernaÂ ndez-Alcoceba et al., 2000).
The ether-linked phospholipid analogues include several families of compounds with antiproliferative, cytotoxic and antitumoral activities whose mechanism of action is poorly understood (Houliham et al., 1995; Storme et al., 1983; Boggs et al., 1995; Geilen et al., 1992; Haase et al., 1991; Wieder et al., 1993; Posse de Chaves et al., 1995; Seewald et al., 1990; U È berall et al., 1991; Pawelczyk et al., 1993; Berkovic et al., 1994; Maly et al., 1995) . They have been reported to inhibit PKC activity in dierent ways, which could account for their antiproliferative capacity (Seewald et al., 1990; U È berall et al., 1991; Pawelczyk et al., 1993; Berkovic et al., 1994; Maly et al., 1995) . Also, HePC can rapidly increase PLD activity in human breast ®broblast cells in a PKC-dependent manner (Wieder et al., 1996) . This surprising eect seems to be contradictory with the antiproliferative activity of the drug.
Our results demonstrate that an acute treatment with HePC on MDCK cells causes the activation of PLD in a PKC-independent manner. However, in keeping with a previous report (Wieder et al., 1996) , a PKCdependent mechanism was found implicated in the activation of PLD in Rat-2 and NIH3T3 cells by acute treatment with HePC. Surprisingly, we provide evidence that a chronic treatment with HePC prevents further stimulation of the enzyme by either phorbol esters or HePC itself. Therefore, HePC causes both homologous and heterologous desensitization of PLD activation. This eect, rather than acute PLD activation, may be in keeping with the antiproliferative and anti-invasive eects of the ether-linked phospholipid analogues.
We have also investigated the eects of HePC on ChoK and showed no inhibitory eect on the enzyme. Thus, this drug with a phospholipid-related structure aects one of the critical enzymes involved in the PLD/ ChoK pathway but has no eect on the other. ChoK inhibitors that interfere with ChoK function but have no eect on PLD, also show antiproliferative and antitumoral actions (HernaÂ ndez-Alcoceba et al., 1997 . Alterations in the balance of the pathways regulating the generation of mitogenic (PCho) and structural signals (PC) may be critical for the integrity of the cells (Lacal and Carnero, 1994; Lacal, 1997) . PLD activation and/or desensitization by HePC would alter the balance of choline-PCho with drastic consequences, connecting the apoptotic program. In this sense, it has been reported recently that treatment of HaCaT cells with HePC induced apoptotic cell death (Haase et al., 1991; Geilen et al., 1992; Detmar et al., 1994; Posse de Chaves et al., 1995) . Although this pathway seems to be important, further research is needed to elucidate the consequences of antitumoral drugs on PLD. The net balance between short activation and desensitization induced by chronic treatment can be important for the ®nal response of the dierent cells to these agents. This novel interpretation may be useful for a better understanding of the mechanisms of action of this family of anticancer drugs.
Materials and methods
Cell culture
MDCK, Rat-2 and HEK 293T cells were grown in DMEM supplemented with 10% fetal calf serum (Gibco) under standard conditions of temperature (378C), humidity (95%) and CO 2 (5%). NIH3T3 mouse ®broblasts were grown in DMEM supplemented with 10% newborn calf serum.
Reagents [ 14 C (U)]Glycerol (148 mCi/mmol) was from Moravek Biochemicals. 1-Butanol was from Merck. PDBu and HePC were purchased from Sigma. GoÈ 6976, GoÈ 6983, and Bisindolylmaleimide was obtained from Calbiochem. Yeast ChoK was from Sigma. Anti-HA antibody was from Boehringer Mannheim.
Assay of PLD activity
PLD activation can be measured by its transphosphatidylating activity in presence of 1-butanol to generate PtdBut (Pazit and Liscovitch, 1989; Song et al., 1991) . MDCK, NIH3T3, or Rat-2 cells were grown in multiwell plates and labeled for 48 ± 72 h in the presence of 1 mCi/ml [ 14 C (U)]Glycerol (148 mCi/mmol). For the downregulation experiments, PDBu or HePC were added to the culture medium during the labeling periods. Time and concentrations are indicated in each case. Inhibition of PKC in MDCK cells was achieved by incubating the cells with GoÈ 6976 for 1 h. To assay PLD activity, labeling medium was discarded and cells were washed with TD buer (137 mM NaCl, 5 mM KCl, 1 mM NaHPO 4 , 20 mM Tris/HCl, pH 7.4) and incubated for 30 min in serum-free DMEM supplemented with 0.5% 1-butanol in the presence of the indicated agonists. Medium was again removed, cells were then scraped in 1 ml of methanol and plates washed once with 0.5 ml of methanol. The two methanol samples were collected and mixed with 2 ml of chloroform and 1 ml of water. The organic phases were dried in a 378C heating block under a nitrogen stream. TLC using Silica gel 60A plates (Whatman; LK6D) separated the lipids. The plates were developed with the upper phase of a mixture of ethylacetate/iso-octane/acetic acid/water (90 : 50 : 20 : 100) (v/v), visualized and quanti®ed using an electronic-autoradiography system (InstantImager, Packard). Counts in PtdBut were normalized for the radioactivity incorporated into total lipids. Analysis of protein levels by Western-blot HEK 293T cells were transfected transiently with dierent isoforms of PLD (PLD1 and PLD2) by the calcium phosphate method as described (Montaner et al., 1999) . Cells were grown in dishes of 60 cm diameter and treated with 15 mM HePC for 24 h. Incubation was terminated by aspirating o media, washing twice with TD buer and addition of 150 ml ice-cold lysis buer (150 mM NaCl, 0.5% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 7.5, 15 mM b-glycerophosphate, 10 mM Na 4 P 2 O 7 , 50 mM NaF, 0.1 mM Na 3 VO 4 , 20 mg/ml leupeptin, 1 mM PMSF). Nuclei and detergent-insoluble material were removed by centrifugation at 10 000 g for 10 min and equal amounts of cell lysate (20 mg) were boiled at 958C for 3 min in SDS ± PAGE sample buer. For Western blot analysis, proteins were electrophoresed onto 8% SDS ± PAGE gels (35% acrylamide, 0.6% bis-acrylamide). Separated proteins were transferred to nitro-cellulose and blocked for 1 h in 5% nonfat dried milk in T-TBS (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.05% Tween-20). Blots were then incubated 1 h with a 1 : 500 dilution of the monoclonal anti-HA antibody (Boehringer ± Mannheim) in the same solution, 30 min with 1 : 1000 biotinylated anti-mouse antibody (Amersham) and 30 min with 1 : 1000 streptavidin-horseradish peroxidase (Amersham). Finally, PLD was detected by the ECL protocol (Amersham).
Ex vivo assays of ChoK activity
Indicated concentrations of HePC or JCR-947A were incubated for 45 min at 378C with 10 mU/ml ChoK from yeast in a buer containing 100 mM Tris pH 8, 100 mM MgCl 2 , 10 mM ATP and 200 mM methyl-[ 14 C]-choline chloride (55 mCi/mmol, 2 mCi/ml) in a ®nal volume of 50 ml. The reaction was stopped on ice by adding 10 ml 500 mM EDTA. Thirty ml of every sample were resolved in thin layer chromatography plates (LK6D Silica gel 60A, Whatman Inc., New Jersey, USA) using as liquid phase 0.9% NaCl : methanol : ammonium hydroxide (50 : 70 : 5; V : V : V). Radioactive metabolites (Choline and Phosphorylcholine) were automatically quanti®ed by an electronic autoradiography system (Instantimager, Packard, Meriden, CT, USA).
For ex vivo assays using mammalian cells extracts, MDCK, or HT29 cells were lysed in the lysis buer (50 mM Tris, 10 mM Na 4 P 2 O 7 , 50 mM NaF, 1 mM Na 3 VO 4 , 20 mg/ml leupeptine, 20 mg/ml aprotinin, 1 mM PMSF, 0.5% Trinton X-100, 0.5% sodium deoxycholate, pH 7.5). Extracts were clari®ed by centrifugation at 15 000 g for 20 min. Two hundred mg of total protein from supernatants were assayed for ChoK activity in the presence of indicated concentrations of either HePC or JCR947, a previously characterized inhibitor of ChoK (HernaÂ ndez-Alcoceba et al., 1997).
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